Fabrication and development of nanotoxicology-test bacterial arrays for the investigation of antibiotics against multi drug-resistant bacteria

Projektinformationen

NANOTESTS

ID Finanzhilfevereinbarung: 275148

Abgeschlossenes Projekt

Startdatum 1 März 2012

Enddatum 28 Februar 2015

Finanziert unter

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Gesamtkosten € 223 669,60

EU-Beitrag € 223 669,60

Koordiniert durch

FUNDACION IMDEA NANOCIENCIA
Spain

Ziel

"Bacterial resistance to antibiotics is one of medicine's most vexing challenges. Most antibiotics initially work really well, killing more than 99.9% of microbes they target. But through mutation and the selection pressure exerted by the antibiotic, a few inevitably manage to survive, and flourish as antibiotic-resistant strains. Hence, new strategies to design antibiotic to combat drug-resistant bacteria are required. Many drug delivery systems based on nanomaterials have been developed during the last decade, being the toxicology of these materials into single bacteria still not thoroughly evaluated due to the lack of reliable techniques to confine individual microbes. Prof. Whitesides' group in Harvard University (USA) is undoubtedly a world leader in this area, as it has a high international profile earned through many key contributions about novel nanofabrication methods for microbiological applications during the last 20 years. Prof. Miranda and Prof. Carrascosa (both from IMDEA Nanoscience-Spain) are the leaders of research groups working in collaboration for (i) the development of novel antibiotic strategies based on drug delivery nano-systems and (ii) biophysical aspects of cell mechanics, self-assembly properties of organic heterostructures and supramolecular nanomachines. The time is ripe to integrate the various strategies developed by Prof. Whitesides’ group to confine single living bacteria with the novel strategies for drug delivery that are being developed at IMDEA Nanoscience-Spain.
The aim of the present OIF includes consolidating IMDEA expertise in the toxicological effect of nanoparticle based drug carriers into individual bacteria in order to develop a novel set of antibiotics for treatment of multi drug-resistant bacteria and to contribute to fundamental questions about bacterial biology, such as cell wall biophysics, chemical bonding and DNA conformational dynamics."

Wissenschaftliches Gebiet

• natural sciences › biological sciences › microbiology › bacteriology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics
• natural sciences › biological sciences › biophysics
• engineering and technology › nanotechnology › nano-materials
• medical and health sciences › basic medicine › toxicology

Programm/Programme

• FP7-PEOPLE - Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Thema/Themen

• FP7-PEOPLE-2010-IOF - Marie Curie Action: "International Outgoing Fellowships for Career Development"

Aufforderung zur Vorschlagseinreichung

FP7-PEOPLE-2010-IOF
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

MC-IOF - International Outgoing Fellowships (IOF)

Koordinator

FUNDACION IMDEA NANOCIENCIA

Kontakt Verwaltung

Villa Maria Jesus (Dr.)

• EU-Beitrag: € 223 669,60
• Adresse: CALLE FARADAY 9 CIUDAD UNIVERSITARIA DE CANTOBLANCO ; 28049 Madrid ; Spanien
• Region: Comunidad de Madrid › Comunidad de Madrid › Madrid
• Aktivitätstyp: Research Organisations
• Gesamtkosten: Keine Daten